Renub Research recently published a report on “Cardiac Maker Analyzer Product Analysis, Business & Marketing Strategy of Cardiac Maker Companies”. The report comprises in-depth analysis by company (products specifications, comparative tests analysis, merger, acquisitions, and agreements), sales & Forecast to 2022.
Cardiac Markers Analyzers generally measure the levels of enzymes and proteins that are linked with injury of the heart muscle. When any damage to the heart muscle occurs, the levels of cardiac markers rise over time that is why blood tests for myocardial infarction are taken over a 24-hour period. These enzymes include Creatine Kinase (CK), Myoglobin, Brain Natriuretic Peptide (BNP), and the proteins Troponin I (TnI), Troponin T (TnT).
Cardiac troponin levels usually remain too low; hence, they cannot be detected with most blood tests and when they are detected, it's usually represents that the heart muscle got damaged due to a myocardial infarction commonly termed as Heart attack. Troponin levels may also remain high for up to 14 days after a heart attack strikes.
Today, a number of companies focused their interest in the development of advanced and highly efficient cardiac markers that perform several cardiac marker tests on their cardio-metabolism platform and established them as the leader in this market. Beckman Coulter offers the maximum number of cardiac marker tests on its cardiology platform while Abbott Laboratories (i-Stat) and Siemens Healthineers (Stratus® CS Analyzer) also offer several cardiac marker tests on their cardio-metabolism platform.
Alere Inc., a renowned name in rapid diagnostic tests, provides reliable and actionable health information through cardiac marker tests, ensuing in better clinical outcomes. Alere’s Cardiology net product sale was more than US$ 600 Million in 2016 and is expected to rule the industry rigorously in the coming future.
Cardiac Marker Analyzers are important for the prevention of the misdiagnoses of cardiac conditions.
A Cardiac Marker Analyzer increases its efficacy and accuracy with special features, such as software, which provides an internal standard to diagnostic procedures and built in LCD displays for the visualization of practices.
The Report Studies the 12 Companies Cardiac Marker Analyzer Product Specifications, Merger, Expansion and Distribution Plans
2. Response Biomedical
3. Abbott Point of Care
5. Siemens Healthineers
6. Beckman Coulter
9. LSI Medience Corporation
10. Trinity Biotech
11. CardioGenics Holdings Inc.
12. Getein Biotechnology
Sr. Marketing Manager
Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.